Literature DB >> 23173675

Quantitative reduction of peripheral CD4+ CD25+ FOXP3+ regulatory T cells in reproductive failure after artificial insemination by donor sperm.

Yuechao Lu1, Fan Zhang, Yang Zhang, Bin Zeng, Lian Hu, Aihua Liao.   

Abstract

PROBLEM: The objective of this study was to determine whether peripheral Treg-cell percentages were altered in women with reproductive failure after artificial insemination by donor sperm (AID) and which parameters can best discriminate women with AID failure and normal controls. METHOD OF STUDY: A retrospective case-control study of 20 fertile controls and 20 patients undergoing more than four treatment cycles with negative pregnancy test (Group I), 20 experiencing biochemical pregnancy loss (Group II), and 20 undergoing missed abortion or spontaneous miscarriage (Group III) was performed. The peripheral percentages of CD4(+) CD25(+) and CD4(+) CD25 (+) Foxp3(+) Treg cells within CD4(+) T-cell population were evaluated at both late follicular and luteal phases of menstrual cycle by flow cytometry.
RESULTS: A significantly decreased percentage of CD4(+) CD25(+) Foxp3(+) Treg cells was detected at the late follicular phase in all AID failure groups compared with the controls. The percentage of CD4(+) CD25(+) Foxp3(+) Treg cells at the late follicular phase in the controls was higher than that at the luteal phase. Using receiver operating characteristic curve, we found that CD4(+) CD25(+) Foxp3(+) Treg-cell percentage <2% can best discriminate the AID failure and normal controls.
CONCLUSION: Reduced percentage of peripheral CD4(+) CD25(+) Foxp3(+) Treg cells at the late follicular phase was associated with AID failure and can be a potential biomarker for predicting AID-induced failure.
© 2012 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23173675     DOI: 10.1111/aji.12041

Source DB:  PubMed          Journal:  Am J Reprod Immunol        ISSN: 1046-7408            Impact factor:   3.886


  7 in total

Review 1.  Regulatory T cells in embryo implantation and the immune response to pregnancy.

Authors:  Sarah A Robertson; Alison S Care; Lachlan M Moldenhauer
Journal:  J Clin Invest       Date:  2018-10-01       Impact factor: 14.808

Review 2.  A new era in reproductive medicine: consequences of third-party oocyte donation for maternal and fetal health.

Authors:  Shigeru Saito; Yasushi Nakabayashi; Akitoshi Nakashima; Tomoko Shima; Osamu Yoshino
Journal:  Semin Immunopathol       Date:  2016-06-20       Impact factor: 9.623

3.  Effect of Intralipid infusion on peripheral blood T cells and plasma cytokines in women undergoing assisted reproduction treatment.

Authors:  Kerrie L Foyle; David J Sharkey; Lachlan M Moldenhauer; Ella S Green; Jasmine J Wilson; Cassandra J Roccisano; M Louise Hull; Kelton P Tremellen; Sarah A Robertson
Journal:  Clin Transl Immunology       Date:  2021-08-12

Review 4.  New Paradigm in the Role of Regulatory T Cells During Pregnancy.

Authors:  Sayaka Tsuda; Akitoshi Nakashima; Tomoko Shima; Shigeru Saito
Journal:  Front Immunol       Date:  2019-03-26       Impact factor: 7.561

5.  CD4+CD25+Foxp3+ regulatory T cells regulate immune balance in unexplained recurrent spontaneous abortion via the Toll-like receptor 4/nuclear factor-κB pathway.

Authors:  Shuang Qin; Li Li; Jia Liu; Jinrui Zhang; Qing Xiao; Yujuan Fan; Xiangcai Wei
Journal:  J Int Med Res       Date:  2020-12       Impact factor: 1.671

Review 6.  Role of Regulatory T Cells in Regulating Fetal-Maternal Immune Tolerance in Healthy Pregnancies and Reproductive Diseases.

Authors:  Ning Huang; Hongbin Chi; Jie Qiao
Journal:  Front Immunol       Date:  2020-06-26       Impact factor: 7.561

7.  VIP Promotes Recruitment of Tregs to the Uterine-Placental Interface During the Peri-Implantation Period to Sustain a Tolerogenic Microenvironment.

Authors:  Lucila Gallino; Vanesa Hauk; Laura Fernández; Elizabeth Soczewski; Soledad Gori; Esteban Grasso; Guillermina Calo; Nora Saraco; Esperanza Berensztein; James A Waschek; Claudia Pérez Leirós; Rosanna Ramhorst
Journal:  Front Immunol       Date:  2020-01-08       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.